Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Furiex Pharmaceuticals Inc    FURX   US36106P1012

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 

Furiex Pharmaceuticals Inc : Furiex Pharmaceuticals Announces Second Quarter 2012 Earnings Release and Conference Call

07/09/2012| 04:10pm US/Eastern
Recommend:
0

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its second quarter 2012 financial results on Thursday, August 2, 2012, after the market closes. The earnings news release will be available on the Furiex website at www.furiex.com.

On Friday, August 3, 2012, at 9 a.m. ET, Furiex will conduct a live conference call and audio webcast to discuss financial results and product portfolio. A Q&A session will follow. The conference call will be broadcast live over the Internet and will also be available using the following direct dial numbers:

Participant dial-in:   +1 877 677 9122 (U.S./Canada)
+1 708 290 1401 (International)
Conference ID: 97824033

All interested parties can access the webcast through the Presentations & Events link in the Investors section of the Furiex website at www.furiex.com. The webcast will be archived shortly after the call for on-demand replay.

About Furiex

Furiex Pharmaceuticals is a drug development collaboration company that uses innovative clinical development design to accelerate and increase value of drug development programs by advancing them through the drug discovery and development process in a cost-efficient manner. Our drug development programs are designed and driven by a core team with extensive drug development experience. The company collaborates with pharmaceutical and biotechnology companies and has a strong, diversified product portfolio and pipeline with multiple therapeutic candidates, including one Phase III-ready asset, two compounds in Phase III development, one of which is with a partner and two products on the market. The company's mission is to develop innovative medicines faster and at a lower cost, thereby improving profitability and accelerating time to market while providing life-improving therapies for patients. For more information, visit www.furiex.com.

Furiex Pharmaceuticals, Inc.
Media/Analysts/Investors:
Sailash Patel, 919-456-7814
sailash.patel@furiex.com


© Business Wire 2012
Recommend :
0
Partner Area
React to this article
 
Latest news on FURIEX PHARMACEUTICALS INC
05/07 FURIEX PHARMACEUTICALS INC: Furiex Reports First Quarter 2013 Financial Results
04/09 FURIEX PHARMACEUTICALS INC: Furiex Pharmaceuticals Announces First Quarter 2013..
04/04 FURIEX PHARMACEUTICALS INC: Furiex Pharmaceuticals to Receive Milestone Payment..
03/06 FURIEX PHARMACEUTICALS INC: Furiex Reports Fourth Quarter and Full Year 2012 Fi..
02/26 FURIEX PHARMACEUTICALS INC: Furiex Pharmaceuticals to Present at Cowen & Compan..
02/25 FURIEX PHARMACEUTICALS INC: Furiex Receives Qualified Infectious Disease Produc..
01/29 FURIEX PHARMACEUTICALS INC: Furiex Pharmaceuticals Announces Fourth Quarter and..
01/25 FURIEX PHARMACEUTICALS INC: Furiex Confirms Takeda's Receipt of FDA Approval of..
2012 FURIEX PHARMACEUTICALS INC: Furiex Reports Third Quarter 2012 Financial Results
2012 FURIEX PHARMACEUTICALS INC: Furiex Pharmaceuticals Announces Third Quarter 2012..
Advertisement
Chart
Duration : Period :
Furiex Pharmaceuticals Inc Technical Analysis Chart | FURX | US36106P1012 | 4-Traders
Income Statement Evolution
Furiex Pharmaceuticals Inc : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.